Redefining Medicine
Our mission is to revolutionise the way the world approaches healthcare. Our focus is on investigational & psychotropic medicines, healthcare technology, and novel consumer health products.
Scroll Down
Who we Are
The Company
Bioxyne is a healthcare business and the parent company of the Breathe Life Sciences Group,focused on life sciences, novel therapeutic goods, pharmaceutical manufacturing and wholesaling.
Through its wholly owned subsidiary, Breathe Life Sciences, Bioxyne provides pharmaceutical manufacturing, wholesale, and distribution services, and own-brand (Dr Watson®)prescription medicines and health products in Australia, Europe, Japan, the United States and the United Kingdom.
Bioxyne is redefining medicine. From investigational medicines, cannabis, MDMA and psilocybin, to health and wellness solutions including probiotics and NADs.
Our Purpose
What we Do
We are advancing the acceptance and approval of investigational medicines and treatment options, including cannabis and psychedelics, for patients with unmet needs.
BLS is a contract drug manufacturer, sponsor, importer, exporter, and wholesale distributor of investigational medicines. Our clients include licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors.
As an Australian pharmaceutical manufacturer, Breathe Life Sciences is licensed by the Therapeutic Goods Administration (TGA), Office of Drug Control (ODC) and QLD Health with licenses to import, export, wholesale, and manufacture GMP certified medicinal products supplied to patients via special access pathways.
Medical Cannabis
+Contract pharmaceutical manufacturing (GMP), wholesale and distribution services for clients in Australia, Europe, and Australasia.
MDMA
+Final dose form manufacturing (GMP) in Australia for supply to authorised prescribers and clinical trials (worldwide).
Psilocybin
+Final dose form manufacturing (GMP) in Australia for supply to authorised prescribers and clinical trials (worldwide).
Health Products
+15 years track record of direct to consumer and retail distribution of own-brand (PCC®, Dr. Watson®) consumer health products in the UK, Australasia, USA.
Our Focus
Purpose, People, Profits
At Bioxyne, we are driven by three core principles, the “3 Ps” — Purpose, People, and Profit.
Our Purpose is to redefine how we prevent, treat, and approach disease, transforming the way health is understood and restored.
We focus on investigational medicines with the potential to improve outcomes and offer new hope to patients who do not respond to conventional treatments.
We strive to create value for all our stakeholders — from our dedicated team and the patients who rely on our therapies, to the shareholders who believe in our mission.
Profit, for us, is not the goal itself but the measure of our success in delivering meaningful innovation and sustainable growth.
Our Capabilities
Our strength lies in the integration of scientific innovation, regulatory excellence, and global reach.
As a licensed pharmaceutical sponsor, we manage the entire lifecycle of investigational and psychotropic medicines — from research and development to manufacturing, quality control, and international distribution. Supported by a network of GACP- and GMP-certified partners, advanced supply chain technology, and a commitment to compliance and transparency, we ensure that every product we deliver meets the highest global standards.
Our Solutions
BXN pharmaceutical activities are spearheaded in Australia, where our wholly owned subsidiary BLS Wholesalers is licensed to import, export, wholesale, and manufacture Schedule 3,4 and 8 medicines including cannabis, MDMA, and Psilocybin. Our manufacturing facility in Brisbane is TGA GMP licensed for final dose form medicines and active pharmaceutical ingredients. We are developing similar manufacturing capabilities in the UK and Europe to better serve our growing client base in these key markets.
